The thrombospondin 1-TGF-β axis in fibrotic renal disease

Nephrology Dialysis Transplantation

Volumn 18, Issue 7, 2003, Pages 1241-1245

  Hugo, Christian ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Fibrotic renal disease; TGF ; Thrombospondin 1; Thrombospondin 1 TGF axis

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTOKINE; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA;

CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; DISEASE COURSE; EDITORIAL; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; KIDNEY FAILURE; KIDNEY FIBROSIS; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN SECRETION;

EID: 0037677200     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg159     Document Type: Editorial

References (36)

1. Lawrence DA. Transforming growth factor-β: a general review. Eur Cytokine Network 1996; 7: 363-374
2. Barcellos-Hoff MH. Latency and activation in the control of TGF-β. J Mam Grand Biol Neoplasia 1996; 1: 351-361
3. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-β 1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100: 768-776
4. Munger JS, Huang X, Kawakatsu H et al. The integrin α v β 6 binds and activates latent TGF β 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319-328
5. Mu D, Cambier S, Fjellbirkeland L et al. The integrin α(v)β8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1. J Cell Biol 2002; 157: 493-507
6. Sheppard D. Integrin-mediated activation of transforming growth factor-β(1) in pulmonary fibrosis. Chest 2001; 120 [Suppl 1]: S49-S53
7. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995; 130: 503-506
8. Lawler JM, Sunday M, Thibert V et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 1998; 101: 982-992
9. Crawford SE, Stellmach V, Murphy-Ullrich JE et al. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 1998; 93: 1159-1170
10. Streit M, Velasco P, Riccardi L et al. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J 2000; 19: 3272-3282
11. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292
12. Bitzer M, Sterzel RB, Böttinger EP. Transforming growth factor-β in renal disease. Kidney Blood Press Res 1998; 21: 1-12
13. Johnson RJ. The glomerular response to injury: progression or resolution? Kidney Int 1994; 45: 1769-1782
14. Akagi Y, Isaka Y, Arai M et al. Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996; 50: 148-155
15. Isaka Y, Brees DK, Ikegaya K et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2: 418-423
16. Kopp JB, Factor VM, Mozes M et al. Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab Invest 1996; 74: 991-1003
17. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45: 522-530
18. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020
19. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-β in kidney disease. Am J Physiol 1994; 35: F829-F842
20. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-β by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000; 11: 59-69
21. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol 1993; 122: 923-932
22. Schultz-Cherry S, Chen H, Mosher D et al. Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin 1. J Biol Chem 1995; 270: 7304-7310
23. Ribeiro S, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to activate TGF-β. J Biol Chem 1999; 274: 13586-13593
24. Grainger DJ, Frow EK. Thrombospondin1 does not activate transforming growth factor β1 in a chemically defined system or in smooth muscle cell cultures. Biochem J 2000; 350: 291-298
25. Abdelouahed M, Ludlow A, Brunner G, Lawler J. Activation of platelet transforming growth factor β-1 in the absence of thrombospondin-1. J Biol Chem 2000; 275: 17933-17936
26. Yehualaeshet T, O'Connor R, Green-Johnson J et al. Activation of rat alveolar macrophage-derived latent transforming growth factor β-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am J Pathol 1999; 155: 841-845
27. Yehualaeshet T, O'Connor R, Begleiter A, Murphy-Ullrich JE, Silverstein R, Khalil N. A CD36 synthetic peptide inhibits bleomycin-induced pulmonary inflammation and connective tissue synthesis in the rat. Am J Respir Cell Mol Biol 2000; 23: 204-212
28. Poczatek MH, Hugo C, Darley-Usmar V, Murphy-Ullrich JE. Glucose stimulation of TGF-β activity in MCs is mediated by thrombospondin-1. Am J Pathol 2000; 157: 1353-1363
29. Yevdokimova N, Wahab NA, Mason RM. Thrombospondin-1 is the key activator of TGF-β1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol 2001; 12: 703-712
30. Wang S, Shiva S, Poczatek MH, Darley-Usmar V, Murphy-Ullrich JE. Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-β activation in mesangial cells. J Biol Chem 2002;277:9880-9888
31. McGregor B, Colon S, Mutin M, Chignier E, Zech P, McGregor J. Thrombospondin in human glomerulopathies. Am J Pathol 1994; 144: 1281-1287
32. Hugo C, Shankland SJ, Pichler R, Couser WG, Johnson RJ. Thrombospondin-1, a TGF-β activating protein, precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. Kidney Int 1998; 53: 302-311
33. Hugo C, Pichler R, Meek R et al. Thrombospondin-1 is expressed by proliferating mesangial cells in vivo and is upregulated by PDGF and bFGF. Kidney Int 1995; 48: 1846-1856
34. Hugo C, Pichler RP, Schulze-Lohoff E et al. Thrombospondin peptides are potent inhibitors of mesangial and endothelial cell proliferation in vitro and in vivo. Kidney Int 1999; 55: 2236-2249
35. Shull MM, Ormsby I, Kier AB et al. Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-699
36. Tang B, Bottinger EP, Jakowlew SB et al. Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 1998; 4: 802-807